Zenith Epigenetics Stock
Zenith Epigenetics Corp. is a research and development biotechnology company focused on new and innovative drugs by leveraging its
Sign up today and learn more about Zenith Epigenetics Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Zenith Epigenetics Stock
Zenith Epigenetics Corp. is a research and development biotechnology company focused on new and innovative drugs by leveraging its proprietary epigenetics platform. The company's epigenetic drug discovery platform functions by inhibiting BET bromodomains, having the potential to impact multiple diseases including autoimmune and oncology.
Funding History
| March 2014 | $8.0M |
|---|---|
| July 2014 | $4.6M |
| May 2015 | $4.0M |
Management
Chief Business Officer
Sanjay Lakhotia
President and CEO
Donald McCaffrey
President and Chief Executive Officer
Julie Cherrington
Chief Scientific Officer
Norman Wong
Vice President of Drug Discovery and Exploratory Development
Michael Yakes
Senior Vice President of Operations
Henrik Hansen
CFO
Brad Cann
Senior Director of Pharmacology
Ravi Jahagirdar
Chief Medical Officer
Joy Zhu
Press
biospace - Oct, 26 2023
Zenith Epigenetics Ltd. Announces Collaboration with Cencora on ZEN-3694bioworld - Oct, 7 2020
Zenith Epigenetics signs CRADA with NCI to develop ZEN-3694 for cancerprnewswire - Dec, 14 2016
Zenith Announces Initiation of Phase 1b Clinical Combination Trial for ZEN-3694EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
